X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (436) 436
humans (434) 434
female (274) 274
male (273) 273
adult (264) 264
infectious diseases (252) 252
hiv infections - drug therapy (223) 223
middle aged (189) 189
immunology (186) 186
aids/hiv (183) 183
hiv (152) 152
hiv infections - virology (131) 131
virology (131) 131
microbiology (112) 112
viral load (110) 110
anti-hiv agents - therapeutic use (106) 106
aids (95) 95
drug therapy, combination (91) 91
hiv infections - immunology (89) 89
cd4 lymphocyte count (86) 86
antiretroviral therapy (82) 82
treatment outcome (76) 76
hiv-1 - genetics (74) 74
human immunodeficiency virus--hiv (74) 74
hiv-1 - drug effects (73) 73
hiv infection (72) 72
drug therapy (70) 70
hiv-1 (67) 67
hiv infections - complications (66) 66
human-immunodeficiency-virus (65) 65
abridged index medicus (64) 64
rna, viral - blood (64) 64
antiretroviral therapy, highly active (62) 62
pharmacology & pharmacy (61) 61
anti-hiv agents - administration & dosage (58) 58
infection (56) 56
antiretroviral drugs (52) 52
aged (51) 51
active antiretroviral therapy (48) 48
therapy (48) 48
hiv-1 - isolation & purification (44) 44
human immunodeficiency virus (44) 44
genotype (43) 43
hiv-1 - physiology (43) 43
risk factors (42) 42
hiv protease inhibitors - therapeutic use (41) 41
research (41) 41
adolescent (40) 40
anti-hiv agents - adverse effects (40) 40
protease inhibitors (40) 40
retrospective studies (40) 40
antiviral agents (37) 37
highly active antiretroviral therapy (37) 37
mutation (37) 37
infections (36) 36
medicine, general & internal (33) 33
clinical trials (32) 32
disease progression (32) 32
hiv-infected patients (32) 32
infected patients (31) 31
italy (31) 31
polymerase chain reaction (31) 31
prospective studies (31) 31
ritonavir - therapeutic use (31) 31
care and treatment (30) 30
disease (30) 30
drug administration schedule (30) 30
prevalence (29) 29
ritonavir (29) 29
viruses (29) 29
cohort (28) 28
follow-up studies (28) 28
health aspects (28) 28
safety (28) 28
cohort studies (27) 27
efficacy (27) 27
hiv patients (27) 27
reverse transcriptase inhibitors - therapeutic use (27) 27
cd4 antigen (26) 26
double-blind method (26) 26
drug resistance, viral (26) 26
hiv-1 - immunology (26) 26
rna (26) 26
treatment failure (26) 26
cerebrospinal fluid (25) 25
dosage and administration (25) 25
immunodeficiency-virus type-1 (25) 25
drug resistance (24) 24
raltegravir (24) 24
antiretroviral therapy, highly active - methods (23) 23
hiv-1-infected patients (23) 23
patients (23) 23
risk (23) 23
time factors (23) 23
zidovudine (23) 23
antiviral agents - therapeutic use (22) 22
haart (22) 22
raltegravir potassium (22) 22
resistance (22) 22
diagnosis (21) 21
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 238 - 246
Summary Background Efavirenz with tenofovir-disoproxil-fumarate and emtricitabine is a preferred antiretroviral regimen for treatment-naive patients infected... 
Internal Medicine | LAMIVUDINE | MEDICINE, GENERAL & INTERNAL | EFFICACY | SAFETY | COMBINATION THERAPY | GUIDELINES | PROTEASE-INHIBITOR | ANTIRETROVIRAL THERAPY | NEVIRAPINE | REGIMENS | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - adverse effects | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Organophosphonates - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Adenine - administration & dosage | Benzoxazines - therapeutic use | Organophosphonates - administration & dosage | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Dosage and administration | Efavirenz | Patient outcomes | Clinical trials | Antiretroviral drugs | Drug therapy | Human immunodeficiency virus--HIV | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9692, pp. 796 - 806
Journal Article
Lancet, The, ISSN 0140-6736, 2007, Volume 369, Issue 9569, pp. 1261 - 1269
Summary Background Raltegravir (MK-0518) is an HIV-1 integrase inhibitor with potent in-vitro activity against HIV-1 strains including those resistant to... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | ANTIRETROVIRAL DRUGS | THERAPY | HIV-1-INFECTED INDIVIDUALS | INFECTION | DRUG-RESISTANCE | PREVALENCE | ENFUVIRTIDE | HIV-1 | Drug Resistance, Multiple | Humans | Middle Aged | Male | HIV Integrase Inhibitors - administration & dosage | Viral Load | Oligopeptides - therapeutic use | Dose-Response Relationship, Drug | Atazanavir Sulfate | Adult | Female | Raltegravir Potassium | Organic Chemicals - administration & dosage | Pyridines - therapeutic use | Double-Blind Method | Organic Chemicals - adverse effects | Organic Chemicals - therapeutic use | Logistic Models | Treatment Outcome | Pyrrolidinones | HIV Integrase Inhibitors - adverse effects | Adolescent | HIV Integrase Inhibitors - therapeutic use | HIV Infections - drug therapy | Aged | Pyridines - pharmacology | Oligopeptides - pharmacology | Viral drug resistance | Care and treatment | Dosage and administration | Drug therapy | HIV infection | Raltegravir | Design | Studies | Antiretroviral drugs | Plasma | Inhibitor drugs | Protease inhibitors | Conferences | Human immunodeficiency virus--HIV | Mortality | Gene expression | Drug resistance | Patients | RNA-directed DNA polymerase | Laboratories | Toxicity | Viruses | Genomes | Randomization | Motivation | Antiretroviral agents | Nucleoside reverse transcriptase inhibitors | Safety | Drug dosages | Integrase | Phenotypes | Effectiveness | Proteinase inhibitors | Ribonucleic acid--RNA | Antiretroviral therapy | CD4 antigen | Non-nucleoside reverse transcriptase inhibitors | Inhibitors | Nucleosides | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2007, Volume 370, Issue 9581, pp. 39 - 48
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2013, Volume 13, Issue 7, pp. 587 - 596
Journal Article
The Lancet, ISSN 0140-6736, 11/2017, Volume 390, Issue 10107, pp. 2063 - 2072
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 3/2013, Volume 207, Issue 5, pp. 740 - 748
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 10/2010, Volume 51, Issue 8, pp. 963 - 972
Background. Abacavir-lamivudine and tenofovir DF-emtricitabine fixed-dose combinations are commonly used as first-line antiretroviral therapies. However, few... 
HIV/AIDS | Body mass index | Antiretrovirals | Hip fractures | HIV | Lumbar spine | Bones | AIDS | Bone density | Biological markers | Hip | INFECTIOUS DISEASES | MYOCARDIAL-INFARCTION | MICROBIOLOGY | ANTIRETROVIRAL THERAPY | PREVALENCE | IMMUNOLOGY | OSTEOPOROSIS | WOMEN | MINERAL DENSITY | NAIVE PATIENTS | MEN | COHORT | HYPERSENSITIVITY | Bone and Bones - pathology | Lamivudine - administration & dosage | Bone Density - physiology | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Lamivudine - adverse effects | Tenofovir | Young Adult | Adenine - adverse effects | Adult | Deoxycytidine - adverse effects | Female | Dideoxynucleosides - adverse effects | Dideoxynucleosides - administration & dosage | Emtricitabine | Adenine - analogs & derivatives | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Europe | Organophosphonates - adverse effects | Absorptiometry, Photon | Adenine - administration & dosage | Organophosphonates - administration & dosage | Bone Density - drug effects | Bone and Bones - physiopathology | Adolescent | HIV Infections - drug therapy | Aged | Deoxycytidine - analogs & derivatives | Drug Combinations | Antiretroviral drugs | Infectious diseases | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Comparative analysis | Drug therapy | Index Medicus
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2008, Volume 359, Issue 4, pp. 339 - 354
Journal Article